Summit Therapeutics (SMMT) Receivables - Other (2017 - 2025)

Summit Therapeutics' (SMMT) quarterly Receivables - Other came in at $12000.0 in Q1 2025, down 86.67% on a QoQ basis from $90000.0 in Q3 2024.

Summit Therapeutics (SMMT) Receivables - Other (2017 - 2025) Analysis & Trends

Summit Therapeutics (SMMT) has 7 years of Receivables - Other data on file, last reported at $12000.0 in Q1 2025.

Quarterly Receivables - Other changed N/A year-over-year to $12000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $12000.0 (changed N/A YoY) and the FY2021 annual result came in at $574000.0, changed N/A from the prior year.
Receivables - Other retreated to $12000.0 in Q1 2025, from $90000.0 in the prior quarter.
In the past five years, Receivables - Other ranged from a high of $1.1 million in Q2 2022 to a low of $12000.0 in Q1 2025.
A 4-year average of $397833.3 and a median of $322500.0 in 2022 frame the typical range for Receivables - Other.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Summit Therapeutics	10.59 Bn	9.90 Bn	-

Download Data